Document:

Exhibit 10.7

ABBOTT LABORATORIES

RESTRICTED STOCK UNIT AGREEMENT

        This
Agreement made «DateAwded» (the “Grant Date”), between Abbott Laboratories, an
Illinois corporation (the “Company”), and «FirstMILast» (the “Employee”), for
the grant by the Company to the Employee of a Restricted Stock Award under the
Company’s 1996 Incentive Stock Program.

        1.    Grant of Shares.    Pursuant
to action of the Compensation Committee of the Board of Directors of the
Company, and in consideration of valuable services heretofore rendered by the
Employee to the Company and of the agreements hereinafter set forth, the
Company has granted to the Employee the right to receive «NoShares»
(«NoShares12345») common shares of the Company (the “Restricted Stock Units” used
herein “Units”) on the Delivery Date. The “Delivery Date” of the shares shall
be the date on which the Restriction (as defined in Section 2 below) on
such Units lapse. Unless indicated otherwise, the shares of stock shall be
delivered in an equal number of shares (subject to rounding) as of each
Delivery Date, if there is more than one Delivery Date applicable. The shares
shall be issued from the Company’s available treasury shares. Prior to the
Delivery Date(s), (a) the Employee shall not be treated as a shareholder
as to those shares, and shall only have a contractual right to receive them,
unsecured by any assets of the Company or the subsidiaries; (b) the
Employee shall not be permitted to vote the Restricted Stock Units; and
(c) the Employee’s right to receive such shares will be subject to the
adjustment provisions relating to mergers, reorganizations, and similar event
set forth in the Plan. The Restricted Stock Units shall be subject to all of
the restrictions hereinafter set forth. The Employee shall be permitted to
receive cash payments equal to the dividends and distributions paid on shares
of stock (other than dividends or distributions of securities of the Company
which may be issued with respect to its shares by virtue of any stock split, combination,
stock dividend or recapitalization) to the same extent as if each Unit was a
share of stock, and those shares were not subject to the restrictions imposed
by this Agreement and the Plan; provided, however, that no dividends or
distributions shall be payable to or for the benefit of the Employee with
respect to record dates for such dividends or distributions occurring on or
after the date, if any, on which the Employee has forfeited the Restricted
Stock Units.

        2.    Restriction.    Until
the restriction imposed by this Section 2 (the “Restriction”) has lapsed
pursuant to Section 3 or 4 below, the Units shall not be sold, exchanged,
assigned, transferred, pledged or otherwise disposed of, and shall be subject
to forfeiture as set forth in Section 5 below.

        3.    Lapse of Restriction by
Passage of Time.    The Restriction shall lapse
and have no further force or effect upon the earlier of: (a) three
(3) years after the date of this Agreement; or (b) employee’s
attainment of age 65.

        4.    Lapse of Restriction by Death
or Disability.    The Restriction shall lapse
and have no further force or effect upon the Employee’s death, disability or
involuntary discharge other than “for cause”. For purposes of this Agreement,
the term “disability” shall mean the Employee’s disability as defined in
subsection 4.1(a) of the Abbott Laboratories Extended Disability Plan for
twelve consecutive months. Once the Employee has been disabled as defined in
this Section for twelve consecutive months, the disability shall be deemed to
have occurred on the first day of such twelve month period. The term discharge “for
cause” shall have the meaning given that term by Section 9.

        5.    Forfeiture of Units.    In
the event of termination of the Employee’s employment with the Company due to
the Employee’s voluntary resignation (including retirement under a Company
pension plan) or involuntary discharge for cause, prior to lapse of the
Restriction under Section 3 or 4, all of the Units shall be forfeited as
of the date of termination, without consideration to the Employee or his
executor, administrator, personal representative or heirs (“Representative”).
In the event the Employee’s employment is terminated due to retirement under a
Company Pension Plan, the Compensation Committee of the Board of Directors of
the Company may, in its sole discretion, waive forfeiture as to any or all of
the Units.

        6.    Withholding Taxes.    The
lapse of the Restriction on the Units pursuant to Section 3 or 4 above or the
delivery of the shares shall be conditioned on the Employee or the
Representative having made appropriate arrangements with the Company to provide
for the withholding of any taxes as may be required to be withheld by federal,
state or local law with respect to such lapse or delivery.

        7.    Rights Not Enlarged.    Nothing
herein confers on the Employee any right to continue in the employ of the
Company or of any of its subsidiaries.

        8.    Succession.    This
Agreement shall be binding upon and operate for the benefit of the Company and
its successors and assigns, and the Employee and his Representative.

 

 

        9.    Discharge for Cause.    The
term discharge “for cause” shall mean termination by the Company of the
Employee’s employment for (A) the Employee’s failure to substantially
perform the duties of his employment (other than any such failure resulting
from the Employee’s disability); (B) material breach by the Employee of
the terms and conditions of his employment; (C) material breach by the
Employee of business ethics; (D) an act of fraud, embezzlement or theft
committed by the Employee in connection with his duties or in the course of his
employment; or (E) wrongful disclosure by the Employee of secret processes
or confidential information of the Company or its subsidiaries.

        IN
WITNESS WHEREOF, the parties have executed this Agreement, on the date first
above written.

 

	
   

  	
  ABBOTT LABORATORIES

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By

  	
  Miles D. White

  Chairman and Chief Executive Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  «FirstMILast»Exhibit
10.8

 

ABBOTT LABORATORIES

1996 INCENTIVE STOCK
PROGRAM

NON-EMPLOYEE DIRECTOR
NON-QUALIFIED STOCK OPTION

 

 

ABBOTT LABORATORIES (THE “COMPANY”) HEREBY GRANTS
TO                                                    ,
A NON-EMPLOYEE DIRECTOR OF THE COMPANY (THE “DIRECTOR”), A NON-QUALIFIED STOCK
OPTION TO PURCHASE FROM TIME TO TIME ALL OR ANY PART OF A TOTAL
OF                 COMMON
SHARES OF THE COMPANY, AT A PRICE OF            PER
SHARE, UPON THE TERMS AND CONDITIONS SET FORTH BELOW.

 

THIS OPTION IS GRANTED
THIS            DAY
OF                                    ,
UNDER THE COMPANY’S 1996 INCENTIVE STOCK PROGRAM (HEREIN CALLED THE “PROGRAM”)
FOR THE PURPOSE OF FURNISHING TO THE DIRECTOR AN APPROPRIATE INCENTIVE TO
INCREASE PROFITS AND ENCOURAGE THE DIRECTOR TO CONTINUE SERVICE WITH THE
COMPANY. TERMS USED HEREIN SHALL HAVE THE SAME MEANING AS IN THE PROGRAM, AND
IN THE EVENT OF ANY INCONSISTENCY BETWEEN THE PROVISIONS HEREOF AND THE
PROVISIONS OF THE PROGRAM, THE PROGRAM SHALL CONTROL.

 

THE TERMS AND CONDITIONS OF THE OPTION ARE AS FOLLOWS:

 

1.                                       THIS OPTION MAY, BUT NEED NOT, BE
EXERCISED IN INSTALLMENTS, BUT MAY NOT UNDER ANY CIRCUMSTANCES BE EXERCISED ON
OR AFTER THE TENTH (10TH) ANNIVERSARY OF THE GRANT DATE.

 

2.                                       IN THE EVENT OF DEATH OF THE HOLDER OF
THE OPTION, THIS OPTION MAY BE EXERCISED WITHIN THE TERM OF THE OPTION AND ONLY
BY THE EXECUTOR OR ADMINISTRATOR OF THE ESTATE OF THE HOLDER OF THE OPTION OR
THE PERSON OR PERSONS TO WHOM RIGHTS UNDER THE OPTION HAVE PASSED BY WILL OR
THE LAWS OF DESCENT AND DISTRIBUTION.

 

3.                                       THIS OPTION IS NOT TRANSFERABLE OTHERWISE
THAN (I) BY WILL OR THE LAWS OF DESCENT AND DISTRIBUTION OR (II) BY THE
DIRECTOR AS A GIFT TO THE DIRECTOR’S SPOUSE, CHILD OR GRANDCHILD (THE
DIRECTOR’S “IMMEDIATE FAMILY”) OR TO A FAMILY TRUST, A FAMILY PARTNERSHIP, A
FAMILY LIMITED LIABILITY COMPANY, OR A SIMILAR ARRANGEMENT FOR THE BENEFIT OF
MEMBERS OF THE DIRECTOR’S IMMEDIATE FAMILY. IT MAY NOT BE ASSIGNED, TRANSFERRED
(EXCEPT AS AFORESAID), PLEDGED OR HYPOTHECATED IN ANY WAY, WHETHER BY OPERATION
OF LAW OR OTHERWISE, AND SHALL NOT BE SUBJECT TO EXECUTION, ATTACHMENT OR
SIMILAR PROCESS. ANY ATTEMPT AT ASSIGNMENT, TRANSFER, PLEDGE, HYPOTHECATION, OR
OTHER DISPOSITION OF THIS OPTION CONTRARY TO THE PROVISIONS

 

1

 

HEREOF, AND THE LEVY OF
ANY ATTACHMENT OR SIMILAR PROCESS UPON THIS OPTION, SHALL BE NULL AND VOID AND
WITHOUT EFFECT.

 

4.                                       THIS OPTION MAY BE EXERCISED ONLY BY
DELIVERING TO THE SECRETARY OR OTHER DESIGNATED EMPLOYEE OF THE COMPANY A WRITTEN
NOTICE OF EXERCISE, SPECIFYING THE NUMBER OF COMMON SHARES WITH RESPECT TO
WHICH THE OPTION IS THEN BEING EXERCISED, AND ACCOMPANIED BY PAYMENT OF THE
FULL PURCHASE PRICE OF THE SHARES BEING PURCHASED IN CASH, OR BY THE SURRENDER
OF OTHER COMMON SHARES OF THE COMPANY HAVING A THEN FAIR MARKET VALUE EQUAL TO
THE PURCHASE PRICE, OR, BY THE DELIVERY OF A PROPERLY EXECUTED EXERCISE NOTICE
TOGETHER WITH A COPY OF IRREVOCABLE INSTRUCTIONS TO A BROKER TO DELIVER
PROMPTLY TO THE COMPANY THE AMOUNT OF SALE OR LOAN PROCEEDS TO PAY THE PURCHASE
PRICE, OR A COMBINATION THEREOF, PLUS PAYMENT IN CASH OR, BY WITHHOLDING OR
DELIVERY OF COMMON SHARES OF THE COMPANY, OF THE FULL AMOUNT OF ANY TAXES WHICH
ARE TO BE WITHHELD AND PAID WITH RESPECT TO SUCH EXERCISE, AND IN THE EVENT THE
OPTION IS BEING EXERCISED BY A PERSON OR PERSONS OTHER THAN THE DIRECTOR, SUCH
APPROPRIATE TAX CLEARANCES, PROOF OF THE RIGHT OF SUCH PERSON OR PERSONS TO
EXERCISE THE OPTION, AND OTHER PERTINENT DATA AS THE COMPANY MAY DEEM
NECESSARY.

 

5.                                       THE COMPANY SHALL NOT BE REQUIRED TO
ISSUE OR DELIVER ANY CERTIFICATE FOR SHARES PURCHASED UPON ANY EXERCISE PENDING
COMPLIANCE WITH ALL APPLICABLE FEDERAL AND STATE SECURITIES AND OTHER LAWS
(INCLUDING ANY REGISTRATION REQUIREMENTS) AND COMPLIANCE WITH THE RULES AND
PRACTICES OF ANY STOCK EXCHANGE UPON WHICH THE COMPANY’S COMMON SHARES ARE
LISTED.

 

6.                                       IN THE EVENT THE PURCHASE PRICE OF THE
SHARES COVERED BY THIS OPTION OR ANY TAXES DUE ON ITS EXERCISE ARE PAID BY THE
SURRENDER OF OTHER COMMON SHARES OF THE COMPANY OR, FOR PAYMENT OF WITHHOLDING
TAXES, BY WITHHOLDING OF SHARES, THE HOLDER OF THE OPTION WILL BE GRANTED AN
OPTION (A “REPLACEMENT OPTION”) TO PURCHASE A NUMBER OF COMMON SHARES EQUAL TO
THE NUMBER OF SHARES SURRENDERED AND/OR WITHHELD, PROVIDED THE THEN FAIR MARKET
VALUE OF THE SHARES COVERED BY THIS OPTION IS AT LEAST TWENTY-FIVE PERCENT
(25%) HIGHER THAN SUCH PURCHASE PRICE. THE PURCHASE PRICE UNDER THE REPLACEMENT
OPTION WILL BE THE FAIR MARKET VALUE OF THE SHARES COVERED BY THE REPLACEMENT
OPTION AS OF THE GRANT DATE OF THE REPLACEMENT OPTION. THE REPLACEMENT OPTION
WILL BE A NON-QUALIFIED STOCK OPTION, FIRST EXERCISABLE SIX (6) MONTHS FROM THE
REPLACEMENT OPTION GRANT DATE, WITH A TERM EQUAL TO THE REMAINDER OF THE TERM
OF THE ORIGINAL OPTION.

 

7.                                       AN ADDITIONAL REPLACEMENT OPTION WILL NOT
BE GRANTED UPON THE EXERCISE OF A PREVIOUSLY ISSUED REPLACEMENT OPTION IF THAT
PREVIOUSLY GRANTED REPLACEMENT OPTION IS EXERCISED IN THE SAME CALENDAR YEAR
THAT IT WAS GRANTED.

 

2

 

8.                                       IN THE EVENT THERE IS A CHANGE IN THE
NUMBER OF ISSUED COMMON SHARES OF THE COMPANY WITHOUT NEW CONSIDERATION TO THE
COMPANY (SUCH AS BY STOCK DIVIDENDS OR STOCK SPLIT-UPS), THEN (I) THE NUMBER OF
SHARES AT THE TIME UNEXERCISED UNDER THIS OPTION SHALL BE CHANGED IN PROPORTION
TO SUCH CHANGE IN ISSUED SHARES; AND (II) THE OPTION PRICE FOR THE UNEXERCISED
PORTION OF THE OPTION SHALL BE ADJUSTED SO THAT THE AGGREGATE CONSIDERATION
PAYABLE TO THE COMPANY UPON THE PURCHASE OF ALL SHARES NOT THERETOFORE
PURCHASED SHALL NOT BE CHANGED.

 

IF THE OUTSTANDING COMMON
SHARES OF THE COMPANY SHALL BE COMBINED, OR BE CHANGED INTO ANOTHER KIND OF
STOCK OF THE COMPANY OR INTO SECURITIES OF ANOTHER CORPORATION, WHETHER THROUGH
RECAPITALIZATION, REORGANIZATION, SALE, MERGER, CONSOLIDATION, ETC., THE
COMPANY SHALL CAUSE ADEQUATE PROVISION TO BE MADE WHEREBY THE PERSON OR PERSONS
ENTITLED TO EXERCISE THIS OPTION SHALL THEREAFTER BE ENTITLED TO RECEIVE, UPON
DUE EXERCISE OF ANY PORTION OF THE OPTION, THE SECURITIES WHICH THAT PERSON
WOULD HAVE BEEN ENTITLED TO RECEIVE FOR COMMON SHARES ACQUIRED THROUGH EXERCISE
OF THE SAME PORTION OF SUCH OPTION IMMEDIATELY PRIOR TO THE EFFECTIVE DATE OF
SUCH RECAPITALIZATION, REORGANIZATION, SALE, MERGER, CONSOLIDATION, SPIN-OFF,
ETC. IF APPROPRIATE, DUE ADJUSTMENT SHALL BE MADE IN THE PER SHARE OR PER UNIT
PRICE OF THE SECURITIES PURCHASED ON EXERCISE OF THIS OPTION FOLLOWING SAID
RECAPITALIZATION, REORGANIZATION, SALE, MERGER, CONSOLIDATION, SPIN-OFF, ETC.

 

IN WITNESS WHEREOF, THE COMPANY HAS CAUSED THIS OPTION
TO BE EXECUTED BY ITS DULY AUTHORIZED OFFICER AS OF THE GRANTING DATE ABOVE SET
FORTH.

 

ABBOTT LABORATORIES

 

 

	
   

  	
   

  
	
  CHAIRMAN OF THE BOARD AND

  
	
  CHIEF EXECUTIVE OFFICER

  	
   

  
			

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]